10 Worst High-Risk High-Reward Growth Stocks To Buy

8. Janux Therapeutics, Inc. (NASDAQ:JANX)

Beta (5Y Monthly): 3.22

3-Year Sales Growth: 42.79%

Number of Hedge Fund Holders: 54

Analyst Upside Potential: 153.89%

Janux Therapeutics, Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company focused on developing novel tumor-activated immunotherapies for cancer treatment. The company utilizes two proprietary bispecific platforms including TRACTr and TRACIr. These platforms aim to create safe and effective therapeutics that guide the immune system to target and eliminate tumors while minimizing harm to healthy tissues.

On March 14, JonesTrading analyst Soumit Roy maintained a Buy rating on the stock. Roy noted that Janux Therapeutics, Inc.’s (NASDAQ:JANX) masking technology is showing strong potential, with best-in-class data. This technology is crucial for the company’s tumor-activated immunotherapies. Moreover, the company is expected to release updated data from its PSMA and EGFR targeting masked T cell engagers in 2025. This could further validate its technology and enhance its clinical-stage programs. The company has a substantial cash position of approximately $1.03 billion, which supports ongoing and future research and development activities. Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the worst high-risk high-reward growth stocks to buy.